UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes, obesity & metabolism, 2012-06, Vol.14 (6), p.565-574

2012

Volltextzugriff (PDF)

OP44 ORAL GLUCOSE LOWERING WITH LINAGLIPTIN PLUS METFORMIN COMPARED WITH LINAGLIPTIN ALONE AS INITIAL TREATMENT IN ASIAN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES AND MARKED HYPERGLYCEMIA

Diabetes research and clinical practice, 2014-11, Vol.106, p.S22-S23

2014

Volltextzugriff (PDF)

P298 L’inhibition du cotransporteur sodium-glucose de type 2 (SGLT2) par l’empagliflozine réduit la microalbuminurie chez les patients atteints de diabète de type 2

Diabetes & metabolism, 2015-03, Vol.41, p.A108-A108

2015

Volltextzugriff (PDF)

P332 Risque d’hypoglycémie chez les patients traités par linagliptine, inhibiteur de la DPP4: données regroupées provenant de 1 489 patients diabétiques de type 2 (DT2) âgés de ≥ 65 ans

Diabetes & metabolism, 2015-03, Vol.41, p.A117-A118

2015

Volltextzugriff (PDF)

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

Diabetes, obesity & metabolism, 2012-04, Vol.14 (4), p.348-357

2012

Volltextzugriff (PDF)

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2012-05, Vol.14 (5), p.470-478

2012

Volltextzugriff (PDF)

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged> or =65years

Diabetes, obesity & metabolism, 2014-11, Vol.16 (11), p.1078-1086

2014

Volltextzugriff (PDF)

Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease

Diabetologia, 2007-09, Vol.50 (9), p.1930-1937

2007

Volltextzugriff (PDF)

P307 Risque cardiovasculaire avec Linagliptin chez des patients atteints de diabète de type 2 : une méta-analyse prédéterminée, prospective et adjudiquée à partir d’un vaste programme de phase III

Diabetes & metabolism, 2012-03, Vol.38, p.A103-A103

2012

Volltextzugriff (PDF)

P285 Linagliptine améliore le contrôle glycémique chez les patients atteints de diabète de type 2 indépendamment de la durée du diabète et de l’insulino-résistance

Diabetes & metabolism, 2012-03, Vol.38, p.A97-A97

2012

Volltextzugriff (PDF)

P308 L’efficacité et l’innocuité de la Linagliptine chez les Patients atteints de diabète de type 2 avec ou sans atteinte rénale : Résultats d’un programme global de phase 3

Diabetes & metabolism, 2012-03, Vol.38, p.A103-A103

2012

Volltextzugriff (PDF)

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

Diabetes, obesity & metabolism, 2015-09, Vol.17 (9), p.868-877

2015

Volltextzugriff (PDF)

Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials

Nutrition, metabolism, and cardiovascular diseases, 2016-10, Vol.26 (10), p.886-892

2016

Volltextzugriff (PDF)

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment

Diabetes, obesity & metabolism, 2014-06, Vol.16 (6), p.560-568

2014

Volltextzugriff (PDF)

P306 L’innocuité et l’efficacité de la Linagliptine chez des patients diabétiques de type 2 avec une insuffisance rénale sévère

Diabetes & metabolism, 2012-03, Vol.38, p.A102-A103

2012

Volltextzugriff (PDF)

P305 Linagliptin fournit une efficacité similaire au glimépiride mais améliore la sécurité cardiovasculaire à 2 ans chez des Patients atteints de diabète de Type 2 insuffisamment contrôlés par metformine

Diabetes & metabolism, 2012-03, Vol.38, p.A102-A102

2012

Volltextzugriff (PDF)

P309 Efficacité et sécurité à long terme de la Linagliptine chez des patients avec le diabète de type 2 et l’insuffisance rénale sévère

Diabetes & metabolism, 2012-03, Vol.38, p.A103-A103

2012

Volltextzugriff (PDF)

Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial

Diabetes, obesity & metabolism, 2015-02, Vol.17 (2), p.136-144

2015

Volltextzugriff (PDF)

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

Diabetes, obesity & metabolism, 2015-03, Vol.17 (3), p.276-284

2015

Volltextzugriff (PDF)

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension

Diabetes, obesity & metabolism, 2012-12, Vol.14 (12), p.1145-1154

2012

Volltextzugriff (PDF)

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

International journal of clinical practice (Esher), 2013-12, Vol.67 (12), p.1283-1293

2013

Volltextzugriff (PDF)

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

Diabetes, obesity & metabolism, 2014-11, Vol.16 (11), p.1078-1086

2014

Volltextzugriff (PDF)

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c < 7% with no hypoglycaemia and no weight gain over 2 years

International journal of clinical practice (Esher), 2013-04, Vol.67 (4), p.317-321

2013

Volltextzugriff (PDF)

Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients

Diabetologia, 2007-07, Vol.50 (7), p.1517-1522

2007

Volltextzugriff (PDF)

Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes

Diabetes, obesity & metabolism, 2013-04, Vol.15 (4), p.364-371

2013

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(94)

Publikationsform

Artikel
(100)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Humans
(56)
Life Sciences & Biomedicine
(52)
Male
(46)
Female
(39)
Middle Aged
(37)
Endocrinology & Metabolism
(35)
Aged
(31)
Diabetes
(30)
Adult
(20)
Diabetes Mellitus, Type 2 - Blood
(20)
Diabetes Mellitus, Type 2 - Drug Therapy
(20)
Biological And Medical Sciences
(19)
Linagliptin
(19)
Medical Sciences
(19)
Internal Medicine
(18)
Type 2 Diabetes
(17)
Diabetes Mellitus
(16)
Double-Blind Method
(15)
Treatment Outcome
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

OP44 ORAL GLUCOSE LOWERING WITH LINAGLIPTIN PLUS METFORMIN COMPARED WITH LINAGLIPTIN ALONE AS INITIAL TREATMENT IN ASIAN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES AND MARKED HYPERGLYCEMIA

P298 L’inhibition du cotransporteur sodium-glucose de type 2 (SGLT2) par l’empagliflozine réduit la microalbuminurie chez les patients atteints de diabète de type 2

P332 Risque d’hypoglycémie chez les patients traités par linagliptine, inhibiteur de la DPP4: données regroupées provenant de 1 489 patients diabétiques de type 2 (DT2) âgés de ≥ 65 ans

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged> or =65years

Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease

P307 Risque cardiovasculaire avec Linagliptin chez des patients atteints de diabète de type 2 : une méta-analyse prédéterminée, prospective et adjudiquée à partir d’un vaste programme de phase III

P285 Linagliptine améliore le contrôle glycémique chez les patients atteints de diabète de type 2 indépendamment de la durée du diabète et de l’insulino-résistance

P308 L’efficacité et l’innocuité de la Linagliptine chez les Patients atteints de diabète de type 2 avec ou sans atteinte rénale : Résultats d’un programme global de phase 3

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment

P306 L’innocuité et l’efficacité de la Linagliptine chez des patients diabétiques de type 2 avec une insuffisance rénale sévère

P305 Linagliptin fournit une efficacité similaire au glimépiride mais améliore la sécurité cardiovasculaire à 2 ans chez des Patients atteints de diabète de Type 2 insuffisamment contrôlés par metformine

P309 Efficacité et sécurité à long terme de la Linagliptine chez des patients avec le diabète de type 2 et l’insuffisance rénale sévère

Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c < 7% with no hypoglycaemia and no weight gain over 2 years

Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients

Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes

Suchergebnisse filtern